Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:43:11.251Z.
Calculation as of: 2026-10-06T18:43:11.251Z.
Quote observation: 2026-10-06T18:40:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79812cd6dc1246c3578cfde2233ee829467ffef9b0062efd9074e0cc555abd58
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$695.18M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$693.75M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$669.92M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$664.48M
EV/EBITDA Ratio
25.98x
TTM Avg
12.95x
3Y Avg
19.43x
5Y Avg
199.83x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | $683.73M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $688.39M | N/A | N/A | N/A | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $690.85M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $695.18M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $693.75M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $669.92M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $668.19M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $667.25M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $664.48M | 25.98x | 12.95x | 19.43x | 199.83x |
| ArriVent BioPharma, Inc. (AVBP)vs › | $659.50M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
